Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
Merck (MRK) Provides Statement Regarding CUBICIN Patent Litigation
November 12, 2015 11:50 AM ESTMerck (NYSE: MRK), known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. Court of Appeals for the Federal Circuit. The decision validated the patent for CUBICIN® (daptomycin for injection) that expires on June 15, 2016, but... More
